{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:14:08Z","timestamp":1793315648847,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd015140","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000}}],"reference-count":146,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015140.pub2","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T06:36:53Z","timestamp":1748327813000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation"],"prefix":"10.1002","volume":"2025","author":[{"given":"Mario","family":"Occhipinti","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Unit; Fondazione IRCSS Istituto Nazionale dei Tumori; Milano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Imbimbo","sequence":"additional","affiliation":[{"name":"Department of Oncology; Oncology Institute of Southern Switzerland, EOC; Bellinzona Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Ferrara","sequence":"additional","affiliation":[{"name":"IRCCS Ospedale San Raffaele; Department of Medical Oncology; Milan Italy"},{"name":"Universit\u00e0 Vita-Salute San Raffaele; Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Simeon","sequence":"additional","affiliation":[{"name":"Medical Statistics Unit, Department of Mental Health and Preventive Medicine; University of Campania \"Luigi Vanvitelli\"; Naples Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Fiscon","sequence":"additional","affiliation":[{"name":"Department of Computer, Control, and Management Engineering \"Antonio Ruberti\"; Sapienza University of Rome; Rome Italy"},{"name":"Institute for Systems Analysis and Computer Science \"A. Ruberti\" (IASI); National Research Council; Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corynne","family":"Marchal","sequence":"additional","affiliation":[{"name":"Marie & Louis Pasteur University; Besan\u00e7on France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[{"name":"Cochrane Evidence Synthesis Unit Germany\/UK, Cochrane Haematology, Institute of Public Health; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Viscardi","sequence":"additional","affiliation":[{"name":"Medical Oncology, Department of Precision Medicine; Universit\u00e0 degli Studi della Campania \"Luigi Vanvitelli\"; Naples Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"issue":"18 suppl","key":"10.1002\/14651858.CD015140.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"LBA7005","DOI":"10.1200\/jco.2010.28.18_suppl.lba7005","article-title":"A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinib in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19","volume":"28","author":"Goss","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"27","key":"10.1002\/14651858.CD015140.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1200\/JCO.2013.51.1816","article-title":"Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study","volume":"31","author":"Goss","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0003|cit3","unstructured":"Gefitinib in treating patients with stage IB, II, or IIIA non-small cell lung cancer that was completely removed by surgery clinicaltrials.gov\/ct2\/show\/NCT00049543"},{"issue":"15 suppl","key":"10.1002\/14651858.CD015140.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"TPS8570","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS8570","article-title":"Icotinib versus vinorelbine\/platinum as adjuvant therapy in stage II-IIIA non-small cell lung cancer with EGFR-mutations: a multicenter, randomized, positive-controlled, phase 3, indication-expanding study (EVIDENCE, CCTC-1501)","volume":"34","author":"He","year":"2016","journal-title":"Journal of Clinical Onocology"},{"issue":"9","key":"10.1002\/14651858.CD015140.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S2213-2600(21)00134-X","article-title":"Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial","volume":"9","author":"He","year":"2021","journal-title":"Lancet, Respiratory Medicine"},{"issue":"3","key":"10.1002\/14651858.CD015140.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"S232","DOI":"10.1016\/j.jtho.2021.01.154","article-title":"FP14.11 Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant NSCLC (EVIDENCE): a randomized, open-label, phase 3 study","volume":"16","author":"Zhou","year":"2021","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0007|cit7","unstructured":"A multi-center, randomized, double-blind, placebo-controlled, phase 3 study of single-agent tarceva (erlotinib) following complete tumor resection and with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have epidermal growth factor receptor (EGFR) positive tumors (RADIANT) http:\/\/clinicaltrialsregister.eu 2006"},{"issue":"15","key":"10.1002\/14651858.CD015140.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"7501","DOI":"10.1200\/jco.2014.32.15_suppl.7501","article-title":"A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC\/FISH) non-small cell lung cancer (NSCLC)","volume":"32","author":"Kelly","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/jco.2014.32.15_suppl.7501","article-title":"A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC\/FISH) non-small cell lung cancer (NSCLC)","volume":"32","author":"Kelly","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"34","key":"10.1002\/14651858.CD015140.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1200\/JCO.2015.61.8918","article-title":"Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): a randomized, double-blind, phase III trial","volume":"33","author":"Kelly","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0011|cit11","unstructured":"A study of erlotinib (tarceva) after surgery with or without adjuvant chemotherapy in non-small cell lung carcinoma (NSCLC) patients who have epidermal growth factor receptor (EGFR) positive tumors (RADIANT) http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00373425 2006"},{"issue":"15 SUPPL. 1","key":"10.1002\/14651858.CD015140.pub2-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"7535","DOI":"10.1200\/jco.2014.32.15_suppl.7535","article-title":"Analysis of treatment duration and safety of adjuvant erlotinib (E) versus placebo (P) after surgery in patients (pts) with non-small cell lung cancer (NSCLC): RADIANT trial","volume":"32","author":"O'Brien","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"15","key":"10.1002\/14651858.CD015140.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"7540","DOI":"10.1200\/jco.2015.33.15_suppl.7540","article-title":"Final follow-up (f\/u) results from RADIANT: a randomized double blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection in patients (pts) with stage IB-IIIA EGFR positive (IHC\/FISH) non-small cell lung cancer (NSCLC)","volume":"33","author":"O'Brien","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"15","key":"10.1002\/14651858.CD015140.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"7520","DOI":"10.1200\/jco.2009.27.15_suppl.7520","article-title":"Biomarker analysis from completely resected NSCLC patients enrolled in an adjuvant erlotinib clinical trial (RADIANT)","volume":"27","author":"Richardson","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD015140.pub2-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"7513","DOI":"10.1200\/jco.2014.32.15_suppl.7513","article-title":"Adjuvant erlotinib (E) versus placebo (P) in non-small cell lung cancer (NSCLC) patients (pts) with tumors carrying EGFR-sensitizing mutations from the RADIANT trial","volume":"32","author":"Shepherd","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0016|cit16","unstructured":"Icotinib for completed resected IB NSCLC with EGFR mutation http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02264210"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"101839","DOI":"10.1016\/j.eclinm.2023.101839","article-title":"Adjuvant icotinib versus observation in patients with completely resected EGFR-mutated stage IB NSCLC (GASTO1003, CORIN): a randomised, open-label, phase 2 trial","volume":"57","author":"Ou","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0018|cit18","unstructured":"A randomized phase III trial of adjuvant gefitinib versus cisplatin and vinorelbine in completely resected (stage II-III) non-small cell lung cancer (NSCLC) patients with mutated EGFR (investigator-initiated multicenter clinical trial) https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-UMIN000006252 2011"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0019|cit19","unstructured":"Biomarker analysis of WJOG6410L\/IMPACT: a randomized phase III trial of adjuvant gefitinib versus cisplatin and vinorelbine in completely resected (Stage II-III) non-small cell lung cancer patients with EGFR mutation http:\/\/rctportal.niph.go.jp\/en\/detail?trial_id=UMIN000044738 2021"},{"issue":"3","key":"10.1002\/14651858.CD015140.pub2-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.21.01729","article-title":"Randomized phase III study of gefitinib versus cisplatin plus vinorelbine for patients with resected stage II-IIIA non-small-cell lung cancer with EGFR mutation (IMPACT)","volume":"40","author":"Tada","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"15 SUPPL","key":"10.1002\/14651858.CD015140.pub2-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"8501","DOI":"10.1200\/JCO.2021.39.15_suppl.8501","article-title":"Adjuvant gefitinib versus cisplatin\/vinorelbine in Japanese patients with completely resected, EGFR-mutated, stage II-III non-small cell lung cancer (IMPACT, WJOG6410L): a randomized phase 3 trial","volume":"39","author":"Tada","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"suppl 11","key":"10.1002\/14651858.CD015140.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"xi21","DOI":"10.1093\/annonc\/mds551","article-title":"Vinorelbine plus cisplatin versus gefitinib in resected non-small cell lung cancer haboring activating EGFR mutation (WJOG6410L)","volume":"23","author":"Tada","year":"2012","journal-title":"Annals of Oncology"},{"issue":"suppl 15","key":"10.1002\/14651858.CD015140.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"TPS7110","DOI":"10.1200\/jco.2012.30.15_suppl.tps7110","article-title":"Vinorelbine plus cisplatin versus gefitinib in resected non-small-cell lung cancer harboring activating EGFR mutation (WJOG6410L)","volume":"30","author":"Tada","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0024|cit24","unstructured":"A late stage clinical trial to investigate the efficacy and safety of AZD9291 versus placebo in patients with stage IB-IIIA non-small cell lung carcinoma, following complete tumour resection with or without adjuvant chemotherapy clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000662-65\/BE 2015"},{"issue":"2","key":"10.1002\/14651858.CD015140.pub2-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.jtho.2021.10.014","article-title":"Postoperative chemotherapy use and outcomes from ADAURA: osimertinib as adjuvant therapy for resected EGFR-mutated NSCLC","volume":"17","author":"Goldman","year":"2022","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000510995","article-title":"Osimertinib as adjuvant therapy in patients (pts) with stage IB-IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA","volume":"43","author":"Grohe","year":"2020","journal-title":"Oncology Research and Treatment"},{"issue":"11","key":"10.1002\/14651858.CD015140.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"S2399","DOI":"10.1016\/j.jtho.2017.11.019","article-title":"Adaura: phase III, double-blind, randomized study of osimertinib versus placebo in EGFR mutation-positive NSCLC post-tumor resection","volume":"12","author":"Herbst","year":"2017","journal-title":"Journal of Thoracic Oncology"},{"issue":"18","key":"10.1002\/14651858.CD015140.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"LBA5","DOI":"10.1200\/JCO.2020.38.18_suppl.LBA5","article-title":"Osimertinib as adjuvant therapy in patients (pts) with stage IB-IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA","volume":"38","author":"Herbst","year":"2020","journal-title":"Journal of Clinical Onoclogy"},{"issue":"17","key":"10.1002\/14651858.CD015140.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"LBA3","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA3","article-title":"Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC)","volume":"41","author":"Herbst","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015140.pub2-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1016\/j.jtho.2022.09.125","article-title":"OA01.09 Adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small cell lung cancer: updated ADAURA results","volume":"18","author":"Herbst","year":"2023","journal-title":"Journal of Thoracic Oncology"},{"issue":"10","key":"10.1002\/14651858.CD015140.pub2-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/JCO.22.02186","article-title":"Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial","volume":"41","author":"Herbst","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"Supplement 2","key":"10.1002\/14651858.CD015140.pub2-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1016\/j.annonc.2022.02.095","article-title":"85P adjuvant osimertinib in patients (pts) with stage IB-IIIA EGFR mutation-positive (EGFRm) NSCLC after complete tumour resection: ADAURA China subgroup analysis","volume":"33","author":"Jie","year":"2022","journal-title":"Annals of Oncology"},{"issue":"9","key":"10.1002\/14651858.CD015140.pub2-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.jtho.2023.05.01","article-title":"Three-year safety, tolerability, and health-related quality of life outcomes of adjuvant osimertinib in patients with resected stage IB to IIIA EGFR-mutated NSCLC: updated analysis from the phase 3 ADAURA trial","volume":"18","author":"John","year":"2023","journal-title":"Journal of Thoracic Oncology"},{"issue":"S8","key":"10.1002\/14651858.CD015140.pub2-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"13497","DOI":"10.1111\/ajco.13497","article-title":"Osimertinib as adjuvant therapy in patients with stage IB-IIIA EGFR mutation-positive (EGFRm) NSCLC after complete tumour resection: ADAURA","volume":"16","author":"John","year":"2020","journal-title":"Asia-Pacific Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015140.pub2-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.1016\/j.jtho.2021.01.291","article-title":"Patient-reported outcomes from ADAURA: osimertinib as adjuvant therapy in patients with resected EGFR mutated (EGFRm) NSCLC","volume":"16","author":"Majem","year":"2021","journal-title":"Journal of Thoracic Oncology"},{"issue":"11","key":"10.1002\/14651858.CD015140.pub2-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"2286\u201396","DOI":"10.1158\/1078-0432.CCR-21-3530","article-title":"Health-related quality of life outcomes in patients with resected epidermal growth factor receptor-mutated non-small cell lung cancer who received adjuvant osimertinib in the phase III ADAURA trial","volume":"28","author":"Majem","year":"2022","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0037|cit37","unstructured":"AZD9291 versus placebo in patients with stage IB-IIIA non-small cell lung carcinoma, following complete tumour resection with or without adjuvant chemotherapy clinicaltrials.gov\/ct2\/show\/NCT02511106 2015"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"suppl_7","key":"10.1002\/14651858.CD015140.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"S1413","DOI":"10.1016\/j.annonc.2022.08.047","article-title":"LBA47 - Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): updated results from ADAURA","volume":"33","author":"Tsuboi","year":"2022","journal-title":"Annals of Oncology"},{"issue":"6","key":"10.1002\/14651858.CD015140.pub2-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"S1378","DOI":"10.1016\/j.annonc.2020.10.349","article-title":"356MO Osimertinib adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) NSCLC (ADAURA): central nervous system (CNS) disease recurrence","volume":"31","author":"Tsuboi","year":"2020","journal-title":"Annals of Oncology"},{"issue":"4","key":"10.1002\/14651858.CD015140.pub2-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"S1177","DOI":"10.1016\/j.annonc.2020.08.2279","article-title":"Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): central nervous system (CNS) disease recurrence","volume":"31","author":"Tsuboi","year":"2020","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015140.pub2-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"S113","DOI":"10.1016\/j.jtho.2021.01.292","article-title":"OA06.04 Postoperative chemotherapy use and outcomes from ADAURA: osimertinib as adjuvant therapy for resected EGFR mutated NSCLC","volume":"16","author":"Wu","year":"2021","journal-title":"Journal of Thoracic Oncology"},{"issue":"4","key":"10.1002\/14651858.CD015140.pub2-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"e533","DOI":"10.1016\/j.cllc.2018.04.004","article-title":"ADAURA: phase III, double-blind, randomized study of osimertinib versus placebo in EGFR mutation-positive early-stage NSCLC after complete surgical resection","volume":"19","author":"Wu","year":"2018","journal-title":"Clinical Lung Cancer"},{"issue":"3","key":"10.1002\/14651858.CD015140.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jtho.2021.10.014","article-title":"Postoperative chemotherapy use and outcomes from ADAURA: osimertinib as adjuvant therapy for resected EGFR-mutated NSCLC","volume":"17","author":"Wu","year":"2021","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1016\/j.annonc.2022.10.324","article-title":"Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): updated results from ADAURA","volume":"33","author":"Wu","year":"2022","journal-title":"Annals of Oncology"},{"issue":"18","key":"10.1002\/14651858.CD015140.pub2-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"35","key":"10.1002\/14651858.CD015140.pub2-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"4827","DOI":"10.2217\/fon-2021-0752","article-title":"A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer","volume":"17","author":"Wu","year":"2021","journal-title":"Future Medicine"},{"issue":"16","key":"10.1002\/14651858.CD015140.pub2-BIB0048|cit48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.8004","article-title":"Adjuvant icotinib of 12 months or 6 months versus observation following adjuvant chemotherapy for resected EGFR-mutated stage II-IIIA non-small-cell lung cancer (ICTAN, GASTO1002): a randomized phase 3 trial","volume":"42","author":"Long","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"11 Suppl 2","key":"10.1002\/14651858.CD015140.pub2-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"S888","DOI":"10.1097\/01.JTO.0000438438.14562.c8","article-title":"A prospective, open-labeled, randomized, multicenter phase II study to evaluate efficacy and safety of erlotinib versus NP chemotherapy as adjuvant therapy in post radical operation stage IIIa NSCLC patients with EGFR 19 or 21 EXON mutation","volume":"8","author":"Yue","year":"2013","journal-title":"Journal of Thoracic Oncology"},{"issue":"11","key":"10.1002\/14651858.CD015140.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"S1789","DOI":"10.1016\/j.jtho.2017.09.423","article-title":"Efficacy and safety of erlotinib versus vinorelbine\/ cisplatin as adjuvant therapy for stage IIIa EGFR mutant NSCLC patients","volume":"12","author":"Yue","year":"2017","journal-title":"Journal of Thoracic Oncology"},{"issue":"11","key":"10.1002\/14651858.CD015140.pub2-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S2213-2600(18)30277-7","article-title":"Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial","volume":"6","author":"Yue","year":"2018","journal-title":"Lancet"},{"issue":"34","key":"10.1002\/14651858.CD015140.pub2-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1200\/JCO.22.00428","article-title":"Updated overall survival and exploratory analysis from randomized, phase II EVAN study of erlotinib versus vinorelbine plus cisplatin adjuvant therapy in stage IIIA epidermal growth factor receptor+ non-small-cell lung cancer","volume":"40","author":"Yue","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0053|cit53","unstructured":"Gefitinib versus vinorelbine\/platinum as adjuvant treatment in stage II-IIIA(N1-N2) NSCLC with EGFR mutation clinicaltrials.gov\/ct2\/show\/NCT01405079 2011"},{"issue":"15","key":"10.1002\/14651858.CD015140.pub2-BIB0054|cit54","first-page":"9005","article-title":"CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation-Final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial","volume":"38","author":"Zhong","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015140.pub2-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.jtho.2018.11.020","article-title":"The unique spatial-temporal treatment failure patterns of adjuvant gefitinib therapy: a post hoc analysis of the ADJUVANT trial (CTONG 1104)","volume":"14","author":"Xu","year":"2019","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.lungcan.2020.09.027","article-title":"Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant non-small-cell lung cancer: results from the ADJUVANT (CTONG1104) study","volume":"150","author":"Zeng","year":"2020","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"7","key":"10.1002\/14651858.CD015140.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1200\/JCO.20.01820","article-title":"Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 phase III trial","volume":"39","author":"Wang","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD015140.pub2-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S1470-2045(17)30729-5","article-title":"Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT\/CTONG1104): a randomised, open-label, phase 3 study","volume":"19","author":"Zhong","year":"2018","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0059|cit59","unstructured":"A multicenter, randomized, open-label, phase III clinical trial of icotinib plus pemetrexed-cisplatin versus pemetrexed-cisplatin as postoperative adjuvant treatment in stage III (N1-N2) non-small cell lung cancer (NSCLC) with EGFR-sensitive mutation www.chictr.org.cn\/com\/25\/showprojen.aspx?proj=120271 2021"},{"issue":"15","key":"10.1002\/14651858.CD015140.pub2-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"7561","DOI":"10.1200\/jco.2009.27.15_suppl.7561","article-title":"A randomized phase II trial of adjuvant chemotherapy with docetaxel (DOC) plus cisplatin (CIS) versus paclitaxel (PAC) plus carboplatin (CAR) in patients with completely resected non-small cell lung cancer (NSCLC): safety and feasibility data from trial TORG 0503","volume":"27","author":"Kubota","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD015140.pub2-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1245\/s10434-014-3586-9","article-title":"Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study","volume":"21","author":"Li","year":"2014","journal-title":"Annals of Surgical Oncology"},{"issue":"15 SUPPL","key":"10.1002\/14651858.CD015140.pub2-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"8521","DOI":"10.1200\/JCO.2021.39.15-suppl.8521","article-title":"Different exposure duration of adjuvant icotinib in stage II-IIIA non-small cell lung cancer patients with positive EGFR mutation (ICOMPARE study): a randomized, open-label phase 2 study","volume":"39","author":"Lyu","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0063|cit63","unstructured":"Adjuvant chemotherapy with or without intercalated icotinib clinicaltrials.gov\/ct2\/show\/NCT03983811 2019"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0064|cit64","unstructured":"Adjuvant afatinib in stage I-III NSCLC with EGFR mutation www.clinicaltrials.gov\/ct2\/show\/NCT01746251 2012"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1200\/PO.20.00301","article-title":"Randomized phase II study of 3 months or 2 years of adjuvant afatinib in patients with surgically resected stage I-III EGFR-mutant non-small-cell lung cancer","volume":"5","author":"Neal","year":"2021","journal-title":"JCO Precision Oncology"},{"issue":"15","key":"10.1002\/14651858.CD015140.pub2-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"e17514","DOI":"10.1200\/jco.2011.29.15_suppl.e17514","article-title":"International tailored chemotherapy adjuvant trial: Itaca trial","volume":"30","author":"Novello","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"15","key":"10.1002\/14651858.CD015140.pub2-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"7505","DOI":"10.1200\/jco.2013.31.15_suppl.7505","article-title":"Results of the prospective, randomized, and customized NSCLC adjuvant phase II trial (IFCT-0801, TASTE trial) from the French Collaborative Intergroup","volume":"31","author":"Soria","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD015140.pub2-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1200\/JCO.2013.53.1525","article-title":"Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE","volume":"32","author":"Wislez","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0069|cit69","doi-asserted-by":"crossref","unstructured":"Tada H Tsuboi M Mistudomi T Aoe M Ichinose Y Nakagawa K Adjuvant therapy with gefitinib (Iressa, ZD1839) following complete resection in Japanese patients with non-small cell lung cancer: safety report of the first 38 patients recruited European Journal of Cancer 2003 1 5 S243 10.1016\/S1359-6349(03)90836-6","DOI":"10.1016\/S1359-6349(03)90836-6"},{"issue":"15 SUPPL. 1","key":"10.1002\/14651858.CD015140.pub2-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"7035","DOI":"10.1200\/jco.2012.30.15_suppl.7035","article-title":"Adjuvant carboplatin, docetaxel, bevacizumab, and erlotinib versus chemotherapy alone in patients with resected non-small cell lung cancer: a randomized phase II study of the Sarah Cannon Research Institute (SCRI)","volume":"30","author":"Waterhouse","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"15 SUPPL","key":"10.1002\/14651858.CD015140.pub2-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"8502","DOI":"10.1200\/JCO.2021.39.15-suppl.8502","article-title":"CTONG1103: final overall survival analysis of the randomized phase 2 trial of erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small cell lung cancer","volume":"39","author":"Hong","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"S602","DOI":"10.1016\/S0959-8049(11)72347-4","article-title":"A national, multi center, randomized, open-label, phase II study of erlotinib versus gemcitabine (GEM) plus cisplatin as neoadjuvant treatment in stage iiia-n2 non-small-cell lung cancer (NSCLC) patients (pts) with activating EGFR mutations (C-tong 1103)","volume":"47","author":"Zhong","year":"2011","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"viii738","DOI":"10.1093\/annonc\/mdy424.058","article-title":"PR CTONG 1103: erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment for stage IIIA-N2 EGFR-mutation non-small cell lung cancer (EMERGING): a randomised study","volume":"29 - suppl 8","author":"Chen","year":"2018","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0074|cit74","unstructured":"A randomized controlled clinical study to assess the effects of icotinib as adjuvant therapy in patients with EGFR mutation and MRD-positive stage IA2-IB non-small cell lung cancer www.chictr.org.cn\/hvshowproject.html?id=235342&v=1.1"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0075|cit75","unstructured":"A late stage clinical trial to investigate the efficacy and safety of osimertinib versus placebo in patients with stage IA2-IA3 non-small cell lung cancer, following complete tumour resection https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2021-004135-89"},{"issue":"Issue 9, Supple","key":"10.1002\/14651858.CD015140.pub2-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1016\/j.jtho.2022.07.172","article-title":"P1.06-01 Adjuvant osimertinib versus placebo in completely resected stage IA2-IA3 EGFR-mutated NSCLC: the ADAURA2 phase III study","volume":"17","author":"Goldman","year":"2022","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0077|cit77","unstructured":"A global study to assess the effects of osimertinib in participants with EGFRm stage IA2-IA3 NSCLC following complete tumour resection http:\/\/clinicaltrials.gov\/ct2\/show\/NCT05120349 2021"},{"issue":"4","key":"10.1002\/14651858.CD015140.pub2-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.cllc.2023.02.002","article-title":"Adjuvant osimertinib versus placebo in completely resected stage IA2-IA3 EGFR-mutated NSCLC: ADAURA2","volume":"24","author":"Tsutani","year":"2023","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.2147\/CMAR.S240275","article-title":"Icotinib as adjuvant treatment for stage II-IIIA lung adenocarcinoma patients with EGFR mutation (ICWIP Study): study protocol for a randomised controlled trial","volume":"12","author":"Liu","year":"2020","journal-title":"Cancer Management and Research"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0080|cit80","unstructured":"Erlotinib hydrochloride in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery (an ALCHEMIST treatment trial) http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02193282 2014"},{"issue":"15 (Suppl)","key":"10.1002\/14651858.CD015140.pub2-BIB0081|cit81","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS9077","article-title":"ALCHEMIST: adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC","volume":"38","author":"Sands","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"16 (Suppl)","key":"10.1002\/14651858.CD015140.pub2-BIB0082|cit82","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS811","article-title":"Efficacy and safety of aumolertinib combined with or without chemotherapy as an adjuvant treatment for stage II-IIIA non-small cell lung cancer following complete tumour resection: the first third-generation EGFR-TKI versus chemotherapy phase III clinical","volume":"42","author":"Tan","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD015140.pub2-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"S289","DOI":"10.1016\/j.jtho.2022.07.498","article-title":"EP05.02-016 Aumolertinib after adjuvant chemotherapy\/ radiotherapy in stage pIIIA-N2 non-small-cell lung cancer with EGFR mutation","volume":"17","author":"Zhang","year":"2022","journal-title":"Journal of Thoracic Oncology"},{"issue":"3 Suppl 7","key":"10.1002\/14651858.CD015140.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0093-7754(03)70010-4","article-title":"Targeting HER1\/EGFR: a molecular approach to cancer therapy","volume":"30","author":"Arteaga","year":"2003","journal-title":"Seminars in Oncology"},{"issue":"20","key":"10.1002\/14651858.CD015140.pub2-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.1158\/1078-0432.CCR-16-0399","article-title":"Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity","volume":"22","author":"Ballard","year":"2016","journal-title":"Clinical Cancer Research"},{"issue":"14","key":"10.1002\/14651858.CD015140.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1021\/jm3003203","article-title":"Irreversible protein kinase inhibitors: balancing the benefits and risks","volume":"55","author":"Barf","year":"2012","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0087|cit87","volume-title":"TNM Classification of Malignant Tumours","author":"Brierley","year":"2016"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0088|cit88","first-page":"CD011430","article-title":"Adjuvant chemotherapy for resected early-stage non-small cell lung cancer","volume":"3","author":"Burdett","year":"2015","journal-title":"Cochrane Database Systematic Reviews"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.lungcan.2019.08.002","article-title":"A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer","volume":"137","author":"Cheng","year":"2019","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0090|cit90","unstructured":"Covidence Veritas Health Innovation 2023"},{"issue":"9","key":"10.1002\/14651858.CD015140.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discovery"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0092|cit92","first-page":"2304","article-title":"Influence of trial sample size on treatment effect estimates: meta-epidemiological study","volume":"346","author":"Dechartres","year":"2013","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0093|cit93","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook 2021"},{"issue":"4","key":"10.1002\/14651858.CD015140.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/JTO.0b013e31824a9022","article-title":"Recurrence dynamics for non-small-cell lung cancer: effect of surgery on the development of metastases","volume":"7","author":"Demicheli","year":"2012","journal-title":"Journal of Thoracic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015140.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"4","key":"10.1002\/14651858.CD015140.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jtho.2016.11.2236","article-title":"Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR-mutated non-small cell lung cancer","volume":"12","author":"Ding","year":"2017","journal-title":"Journal of Thoracic Oncology"},{"issue":"9","key":"10.1002\/14651858.CD015140.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1470-2045(06)70804-X","article-title":"Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial","volume":"7","author":"Douillard","year":"2006","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0098|cit98","volume-title":"AJCC Cancer Staging Manual","author":"Edge","year":"2010"},{"issue":"7109","key":"10.1002\/14651858.CD015140.pub2-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"10308","key":"10.1002\/14651858.CD015140.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0101|cit101","first-page":"e214932","article-title":"Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US","volume":"October","author":"Ganti","year":"2021","journal-title":"JAMA Oncology"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0102|cit102","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2021"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0103|cit103","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3656-4","volume-title":"AJCC Cancer Staging Manual","author":"Greene","year":"2002"},{"issue":"13","key":"10.1002\/14651858.CD015140.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1200\/JCO.2001.19.13.3267","article-title":"Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies","volume":"19","author":"Hidalgo","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD015140.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0106|cit106","unstructured":"Higgins JP Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/ 2021"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0107|cit107","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook 2021"},{"issue":"13","key":"10.1002\/14651858.CD015140.pub2-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1158\/1078-0432.CCR-06-0462","article-title":"Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib","volume":"12","author":"Jackman","year":"2006","journal-title":"Clinical Cancer Research"},{"issue":"6","key":"10.1002\/14651858.CD015140.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1158\/2159-8290.CD-16-1337","article-title":"Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies","volume":"7","author":"Jordan","year":"2017","journal-title":"Cancer Discovery"},{"issue":"27","key":"10.1002\/14651858.CD015140.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1200\/JCO.2012.45.0981","article-title":"LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both","volume":"31","author":"Katakami","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD015140.pub2-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.jtho.2017.05.018","article-title":"A higher proportion of the EGFR T790M mutation may contribute to the better survival of patients with Exon 19 deletions compared with those with L858R","volume":"12","author":"Zhou","year":"2017","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1200\/EDBK_159514","article-title":"Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"35","author":"Kluetz","year":"2016","journal-title":"American Society of Clinical Oncology Educational Book"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0113|cit113","unstructured":"Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Metzendorf MI Chapter 4: searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane 2021 Available from training.cochrane.org\/handbook 2021"},{"issue":"4","key":"10.1002\/14651858.CD015140.pub2-BIB0114|cit114","doi-asserted-by":"publisher","first-page":"101565","DOI":"10.1016\/j.esmoop.2023.101565","article-title":"Randomized phase II adjuvant trial to compare two treatment durations of icotinib (2 years versus 1 year) for stage II-IIIA EGFR-positive lung adenocarcinoma patients (ICOMPARE study)","volume":"8","author":"Lv","year":"2023","journal-title":"ESMO Open"},{"issue":"21","key":"10.1002\/14651858.CD015140.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015140.pub2-BIB0116|cit116","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002278","article-title":"Fluoride toothpastes for preventing dental caries in children and adolescents","author":"Marinho","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD015140.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/JTO.0b013e318160c607","article-title":"Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma","volume":"3","author":"Marks","year":"2008","journal-title":"Journal of Thoracic Oncology"},{"issue":"4","key":"10.1002\/14651858.CD015140.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy forcompletely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis ofa randomised, triple-blind, phase 3 trial","volume":"23(10)","author":"O'Brien","year":"2022","journal-title":"Lancet Oncology"},{"issue":"36","key":"10.1002\/14651858.CD015140.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \"never smokers\" and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"11","key":"10.1002\/14651858.CD015140.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nrc2947","article-title":"Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer","volume":"10","author":"Pao","year":"2010","journal-title":"Nature Reviews Cancer"},{"issue":"24","key":"10.1002\/14651858.CD015140.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group","volume":"26","author":"Tribodet","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD015140.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28 Suppl 4","author":"Postmus","year":"2017","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"100152","DOI":"10.1016\/j.crphar.2022.100152","article-title":"Sex differences in drug effects and\/or toxicity in oncology","volume":"24","author":"Rakshith","year":"2023","journal-title":"Current Research in Pharmacology and Drug Discovery"},{"issue":"1","key":"10.1002\/14651858.CD015140.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0128|cit128","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","year":"2014","journal-title":"Pharmacological Research"},{"issue":"3","key":"10.1002\/14651858.CD015140.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/1040-8428(94)00144-I","article-title":"Epidermal growth factor-related peptides and their receptors in human malignancies","volume":"19","author":"Salomon","year":"1995","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"11","key":"10.1002\/14651858.CD015140.pub2-BIB0131|cit131","doi-asserted-by":"publisher","first-page":"e2131892","DOI":"10.1001\/jamanetworkopen.2021.31892","article-title":"Association of clinicopathologic and molecular tumor features with recurrence in resected early-stage epidermal growth factor receptor-positive non-small cell lung cancer","volume":"4","author":"Saw","year":"2021","journal-title":"JAMA Network Open"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0132|cit132","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook 2021"},{"issue":"75","key":"10.1002\/14651858.CD015140.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Science Translational Medicine"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0134|cit134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/25152459221120427","article-title":"Beyond random effects: when small-study findings are more heterogeneous","volume":"5","author":"Stanley","year":"2022","journal-title":"Sage Journals"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"31","key":"10.1002\/14651858.CD015140.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"5043","DOI":"10.1200\/JCO.2008.16.4855","article-title":"Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the cancer and leukemia group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups","volume":"26","author":"Strauss","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015140.pub2-BIB0137|cit137","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: a Cancer Journal for Clinicians"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"25","key":"10.1002\/14651858.CD015140.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1056\/NEJMoa043623","article-title":"Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer","volume":"352","author":"Winton","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"18","key":"10.1002\/14651858.CD015140.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD015140.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncology"},{"issue":"11","key":"10.1002\/14651858.CD015140.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncology"},{"issue":"48","key":"10.1002\/14651858.CD015140.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"78985","DOI":"10.18632\/oncotarget.12587","article-title":"The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1002\/14651858.CD015140.pub2-BIB0144|cit144","doi-asserted-by":"publisher","first-page":"s12885","DOI":"10.1186\/s12885-023-11194-6","article-title":"Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials","volume":"719","author":"Zhang","year":"2023","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1002\/14651858.CD015140.pub2-BIB0145|cit145","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12957-023-02925-x","article-title":"Epidermal growth factor receptor inhibitors as adjuvant treatment for patients with resected non-small cell lung cancer harboring EGFR mutation: a meta-analysis of randomized controlled clinical trials","volume":"21","author":"Zhao","year":"2023","journal-title":"World Journal of Surgical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD015140.pub2-BIB0146|cit146","first-page":"88","article-title":"Chinese guidelines on the diagnosis and treatment of primary lung cancer","volume":"4","author":"Zhi","year":"2012","journal-title":"Journal of Thoracic Disease"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T05:35:47Z","timestamp":1792992947000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015140.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":146,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015140.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]}}}